Stephen L. George, PhD


email this

Professor of Biostatistics and Bioinformatics
Biostatistics & Bioinformatics
2424 Erwin Road Ste 1102
11082 Hock Plaza
Durham, NC 27705
Office Telephone:
(919) 681-5003
  • PhD, Southern Methodist University, 1969
Research Interests:
Statistical issues related to the design, conduct, and analysis of clinical trials and related biomedical studies including sample size and study length determinations, sequential procedures, and the analysis of prognostic or predictive factors in clinical trials.
Representative Publications:
  • Baer, MR; George, SL; Sanford, BL; Mrózek, K; Kolitz, JE; Moore, JO; Stone, RM; Powell, BL; Caligiuri, MA; Bloomfield, CD; Larson, RA; Cancer and Leukemia Group B. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25:800-807.  Abstract
  • Buyse, M; Squifflet, P; Lange, BJ; Alonzo, TA; Larson, RA; Kolitz, JE; George, SL; Bloomfield, CD; Castaigne, S; Chevret, S; Blaise, D; Maraninchi, D; Lucchesi, KJ; Burzykowski, T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117:7007-7013.  Abstract
  • Michiels, S; Potthoff, RF; George, SL. Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Statistics in Medicine. 2011;30:1502-1518.  Abstract
  • Sohn, I; Owzar, K; Lim, J; George, SL; Mackey Cushman, S; Jung, SH. Multiple testing for gene sets from microarray experiments. BMC Bioinformatics. 2011;12:209.  Abstract
  • Kolitz, JE; George, SL; Marcucci, G; Vij, R; Powell, BL; Allen, SL; DeAngelo, DJ; Shea, TC; Stock, W; Baer, MR; Hars, V; Maharry, K; Hoke, E; Vardiman, JW; Bloomfield, CD; Larson, RA; Cancer and Leukemia Group B. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413-1421.  Abstract
  • Sargent, DJ; George, SL. Clinical trials data collection: when less is more. Journal of Clinical Oncology. 2010;28:5019-5021.  Abstract
  • Shterev, ID; Jung, SH; George, SL; Owzar, K. permGPU: Using graphics processing units in RNA microarray association studies. BMC Bioinformatics. 2010;11:329.  Abstract
  • Sohn, I; Owzar, K; George, SL; Kim, S; Jung, SH. Robust test method for time-course microarray experiments. BMC Bioinformatics. 2010;11:391.  Abstract
  • Jung, SH; George, SL. Between-arm comparisons in randomized Phase II trials. Journal of Biopharmaceutical Statistics. 2009;19:456-468.  Abstract
  • Jung, SH; Sohn, I; George, SL; Feng, L; Leppert, PC. Sample size calculation for microarray experiments with blocked one-way design. BMC Bioinformatics. 2009;10:164.  Abstract
  • Potthoff, RF; George, SL. Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations. Statistics in Biopharmaceutical Research. 2009;1:213-228.  Abstract
  • Sohn, I; Owzar, K; George, SL; Kim, S; Jung, SH. A permutation-based multiple testing method for time-course microarray experiments. BMC Bioinformatics. 2009;10:336.  Abstract
  • Baer, MR; George, SL; Caligiuri, MA; Sanford, BL; Bothun, SM; Mrózek, K; Kolitz, JE; Powell, BL; Moore, JO; Stone, RM; Anastasi, J; Bloomfield, CD; Larson, RA. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology. 2008;26:4934-4939.  Abstract
  • Demark-Wahnefried, W; George, SL; Switzer, BR; Snyder, DC; Madden, JF; Polascik, TJ; Ruffin, MT; Vollmer, RT. Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clinical Trials. 2008;5:262-272.  Abstract
  • Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3577-3587.  Abstract
  • George, SL. Statistical issues in translational cancer research. Clinical Cancer Research. 2008;14:5954-5958.  Abstract
  • Green, MR; George, SL; Schilsky, RL; Cancer and Leukemia Group B. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Seminars in Oncology. 2008;35:470-483.  Abstract
  • Owzar, K; Barry, WT; Jung, SH; Sohn, I; George, SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clinical Cancer Research. 2008;14:5959-5966.  Abstract
  • Freidlin, B; Korn, EL; George, SL; Gray, R. Randomized clinical trial design for assessing noninferiority when superiority is expected. Journal of Clinical Oncology. 2007;25:5019-5023.  Abstract
  • George, SL. Response rate as an endpoint in clinical trials. Journal of National Cancer Institute. 2007;99:98-99.  Abstract
  • Dilts, DM; Sandler, AB; Baker, M; Cheng, SK; George, SL; Karas, KS; McGuire, S; Menon, GS; Reusch, J; Sawyer, D; Scoggins, M; Wu, A; Zhou, K; Schilsky, RL; Case of Cancer and Leukemia Group B. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24:4553-4557.  Abstract
  • Jung, SH; Owzar, K; George, SL; Lee, T. P-value calculation for multistage phase II cancer clinical trials. Journal of Biopharmaceutical Statistics. 2006;16:765-775.  Abstract